ClinicalTrials.gg
Active, not recruitingNCT06700343Updated Sep 22, 2026

Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)

A Phase 3 interventional study of Ocrelizumab (US) and Ocrelizumab (EU) in Relapsing-remitting Multiple Sclerosis (RRMS), sponsored by Amgen. Active, not recruiting at 109 sites in 22 countries. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-09-22.

Sponsored by Amgen · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
152
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 229 studies in Multiple Sclerosis, Relapsing-Remitting with a site in United States — 26 open to participants now, 44 under way, 7 of them phase 3. Multiple Sclerosis, Relapsing-Remitting · United States.

Enrollment
57th of 175
152 · median 65
Started
2025
with 9 others
Phase 3
51 of 229
2 open now
Primary completion
2027-04
later than 23 of 43 live
Registered
212th of 229
by date

Among the 229 studies in Multiple Sclerosis, Relapsing-Remitting with a site in United States, this one is the 57th largest by enrollment of the 175 interventional ones that give a count, is one of 10 that started in 2025, is one of 51 in phase 3, reaches primary completion later than 23 of the 43 other live ones, and was the 212th registered.

Multiple Sclerosis, Relapsing-Remitting

618 studies on the registry are indexed under Multiple Sclerosis, Relapsing-Remitting; 83 are open to participants now.

Browse Multiple Sclerosis, Relapsing-Remitting studies →

Open to participants now

26 of the 229 studies in Multiple Sclerosis, Relapsing-Remitting with a site in United States are open now. Recruiting first, the newest first:

21 more — sign in →

All 26 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 61 Multiple Sclerosis, Relapsing-Remitting studies recruiting now, 11 (18%) set no upper age limit and 44 (72%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 229 studies in Multiple Sclerosis, Relapsing-Remitting with a site in United States, or all of them as a file.
02

Study summary

The Main objectives of the study are to demonstrate pharmacokinetic (PK) similarity between ABP 692 and ocrelizumab (US), as well as between ABP 692 and ocrelizumab (EU).

03

Conditions studied

  • Relapsing-remitting Multiple Sclerosis (RRMS)

Keywords

  • Neuroscience
  • Neurology
  • Neuroimmunology
  • Immunosuppressants
  • Ocrelizumab
  • ABP 692
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnosis of RRMS in accordance with the revised McDonald Criteria 2017 (Thompson et al, 2018).
  2. Expanded Disability Status Scale score at screening ≥ 0 and ≤ 5.5 inclusive.
  3. Evidence of recent MS activity as defined by the study protocol.
  4. Neurologically stable subject, with no relapse for ≤ 28 days before randomization.

Exclusion criteria

Exclusion Criteria:

  1. Diagnosis of primary progressive or with secondary progressive MS (Thompson et al, 2018).
  2. Multiple sclerosis disease duration of ≥ 10 years in Participants with Expanded Disability Status Scale (EDSS) score of ≤ 2.5 at screening.
  3. Any to study procedures or medications as outlined in the study protocol.
  4. Any prohibited medication as defined in the study protocol.
  5. Any significant concomitant disease that may require chronic treatment with systemic and/or systemic during the study.
  6. Current or history of any significant medical conditions as described in the study protocol.
  7. Any abnormal laboratory blood values as defined in the study protocol.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
152 participants (actual)

Study arms

  • Experimental
    ABP 692

    Participants affected by relapsing-remitting multiple sclerosis (RRMS) will receive an initial dose of 300 mg ABP 692 intravenous (IV) infusion on Day 1, followed by a second dose of 300 mg ABP 692 IV infusion on Day 15. A subsequent dose of 600 mg ABP 692 IV infusion will be administered 24 weeks after the initial dose.

    Drug: ABP 692

  • Active comparator
    Ocrelizumab (US)/ABP 692

    Participants affected by RRMS will receive an initial dose of 300 mg Ocrelizumab (US) IV infusion on Day 1, followed by a second dose of 300 mg Ocrelizumab (US) IV infusion on Day 15. At Week 24, the treatment will switch to a 600 mg IV infusion of ABP 692.

    Drug: Ocrelizumab (US) · Drug: ABP 692

  • Active comparator
    Ocrelizumab (EU)

    Participants affected by RRMS will receive an initial dose of 300 mg Ocrelizumab (EU) IV infusion on Day 1, followed by a 300 mg Ocrelizumab (EU) IV infusion on Day 15. At Week 24, participants will receive a dose of 600 mg Ocrelizumab (EU) IV infusion.

    Drug: Ocrelizumab (EU)

Interventions

06

What researchers measure

Primary outcomes

  1. Area Under the Serum Concentration-time Curve (AUC) From Time 0 to Day15 (AUC0-d15) Following Infusion 1 ofthe Initial Dose of InvestigationalProduct (IP)

    Time frame: Day 1 to Day 15

  2. AUC From Time 0 Extrapolated toInfinity (AUC0-inf) of the Entire Initial Dose of IP

    Time frame: Day 1 to Week 16

Secondary outcomes

  1. Maximum Concentration (Cmax) Following Infusion 1 of the Initial Dose of IP at Day 1 (Cmax, d1)

    Time frame: Day 1 to Day 15

  2. Cmax Following Infusion 2 of theInitial Dose of IP at Day 15 (Cmax,d15)

    Time frame: Day 15 to Week 16

  3. AUC of the Initial Dose From Time 0 to Week 16 (AUC0-wk16) of IP

    Time frame: Day 1 to Week 16

  4. AUC of Infusion 2 of IP From Day 15 to Week 16 (AUCd15-wk16)

    Time frame: Day 15- Week 16

  5. Time at Which Cmax, d1 (Tmax, d1) of IP is Observed

    Time frame: Day 1 to Day 15

  6. Time at Which Cmax, d15 (Tmax, d15) of IP is Observed

    Time frame: Day 15 to Week 16

  7. Trough Concentration (Ctrough) of IP at Day 15

    Time frame: Day 15

  8. Clearance (CL) of IP

    Time frame: Day 1 to Week 16

  9. Volume of Distribution (Vd) of IP

    Time frame: Day 1 to Week 16

  10. Terminal Elimination Half-life (T1/2) of IP

    Time frame: Day 1 to Week 16

  11. Mean Residence Time (MRT) of IP

    Time frame: Day 1 to Week 16

  12. Total number of new gadolinium enhancing (GdE) T1-weighted lesions at week 12 and week 24

    Time frame: Up to Week 24

  13. Total number of GdE T1-weighted lesions at week 12 and week 24

    Time frame: Up to Week 24

  14. Total Number of New or Enlarging T2 Hyperintense Lesion at Week 12 and week 24

    Time frame: Up to Week 24

  15. Percentage of Participants Achieving < 5 CD19+ B-cells/μL in Peripheral Blood at Week 24

    Time frame: At Week 24

  16. Percentage of Participants Achieving < 10 CD19+ B-cells/μL in Peripheral Blood at Week 24

    Time frame: At Week 24

  17. Percentage of Participants Achieving < 5 CD19+ B-cells/μL in Peripheral Blood at Week 48

    Time frame: At Week 48

  18. Percentage of Participants Achieving < 10 CD19+ B-cells/μL in Peripheral Blood at Week 48

    Time frame: At Week 48

  19. Percentage of Participants who are Relapse-free at Week 24

    Time frame: At Week 24

  20. Percentage of Participants who are Relapse-free at Week 48

    Time frame: At Week 48

  21. Number of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)

    An adverse event (AE) is any untoward medical occurrence in a clinical study participant irrespective of a causal relationship with the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a treatment, combination product, medical device, or procedure. A TEAE is defined as an AE that starts or worsens on or after the first IP infusion up to the end of study visit.

    Time frame: Up to Week 72

  22. Number of Participants Experiencing Treatment-emergent Serious Adverse Events (TESAEs)

    Time frame: Up to Week 72

  23. Number of Participants Experiencing Treatment-emergent Events of Interest (EOIs)

    Time frame: Up to Week 72

  24. Percentage of Participants with Anti-drug Antibodies (ADAs)

    Time frame: Up to Week 48

07

Study locations

109 sites

Showing the first 100 of 109 sites across 22 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · www.amgen.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Apr 2027, 27 months after the start.

Of 28 industry-sponsored phase 3 interventional studies under Multiple Sclerosis, Relapsing-Remitting, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 65. This study's planned 27 months is below that.

Counting every sponsor, half of 38 studies reached it within 48 months; a quarter within 27 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 15, 2024
First posted
Nov 22, 2024
StartActual
Jan 13, 2025
Primary completionEst.
Apr 19, 2027
CompletionEst.
Oct 4, 2027
Last update
Sep 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06700343
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Nov 22, 2024
Start date
Jan 13, 2025
Primary completion
Apr 19, 2027 (estimated)
Completion
Oct 4, 2027 (estimated)
Last update
Sep 22, 2026

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion